GlassScriptPhysician profile
Amna Ramzan
NPI 1063953297
$4,305.01
in general payments reported to CMS, 2019-2025
33 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.44 · 2022: $223 · 2023: $1,039 · 2024: $1,404 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,870 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,869.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.65 | 2023-2025 | |
| Ucb, INC. | $549.06 | 2022-2025 | Zilbrysq, Briviact, Nayzilam |
| Eisai INC. | $431.25 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $418.59 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.32 | 2022-2024 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $173.22 | 2023-2025 | Ultomiris |
| Grifols USA, LLC | $160.34 | 2023-2025 | Gamunex-C |
| Lilly USA, LLC | $159.35 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Csl Behring | $156.90 | 2021-2025 | Hizentra |
| Pfizer INC. | $153.36 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $125.32 | 2024-2025 | Nuplazid |
| Calliditas Therapeutics US INC. | $121.18 | 2022 | |
| Neurocrine Biosciences, INC. | $110.78 | 2023-2024 | Ingrezza, Ongentys |
| Jazz Pharmaceuticals INC. | $109.72 | 2023 | |
| Sk Life Science, INC. | $103.10 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $100.27 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $53.83 | 2023-2024 | Ocrevus, Evrysdi |
| Averitas Pharma INC. | $51.19 | 2023 | Qutenza |
| Merz Pharmaceuticals, LLC | $44.96 | 2023-2024 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $40.32 | 2024 | Austedo Xr |
| Corium, LLC | $29.99 | 2023 | Adlarity |
| Biogen, INC. | $29.56 | 2023-2024 | Vumerity, Tysabri |
| Tg Therapeutics, INC. | $26.15 | 2025 | |
| Lundbeck LLC | $20.89 | 2025 | Vyepti |
| Abbott Laboratories | $20.33 | 2025 | Infinity |
| Genzyme Corporation | $19.09 | 2024 | |
| Axsome Therapeutics, INC. | $18.70 | 2025 | Symbravo |
| Scilex Pharmaceuticals INC. | $17.26 | 2023 | Ztlido |
| Astrazeneca Pharmaceuticals LP | $16.61 | 2025 | Tezspire |
| Avion Pharmaceuticals | $14.67 | 2023 | Dhivy |
| Sumitomo Pharma America, INC. | $14.43 | 2023 | Aptiom |
| Inspire Medical Systems, INC. | $14.18 | 2024 | Inspire |
| Tanabe Pharma America, INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amna Ramzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.